IsoRay, Inc. (NYSE MKT:ISR) Q4 2020 Earnings Conference Call - Final Transcript

Sep 17, 2020 • 04:30 pm ET


IsoRay, Inc. (NYSE MKT:ISR) Q4 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript

Lori A. Woods

the treatment of prostate cancer. In fact, we are particularly taken by the express thoughts of the authors who commenting together said, and I quote"the shorter duration of urinary morbidity along with the lack of differences in long-term adverse effects support our preference for this isotope" The authors concluded the study demonstrated that in their words prostate brachytherapy treated with Cesium-131 achieves excellent long-term biochemical control. This observational study from the University of Pittsburgh School of Medicine combined with the Chicago Prostate Cancer Center Dtudy published in September of 2019 represents comprehensive long-term data that demonstrates Cesium-131's success in treating low and intermediate localized prostate cancer. The studies underscore that Cesium-131's short half life and high energy allow to aggressively attack the cancer, while reducing the potential for side effects patients may otherwise experience from prolonged radiation exposure. We believe that the growing list of long-term data should continue to help highlight the differentiating and unique qualities of Cesium-131 versus other isotopes in the treatment of prostate cancer. Beyond our success in prostate, we are continuing our efforts to build on our progress in bringing the therapeutic benefits of Cesium-131, as a treatment options for cancers throughout the body. We are very excited about the Phase I B study, we shared with you in our recent press release. As you may remember, the study will evaluate the safety and efficacy of the immunotherapy drug KEYTRUDA and Cesium-131, following surgical resection. As a treatment option for recurrent head and neck cancers. Through a research grant agreement between IsoRay and the University of Cincinnati Physicians Company, the trial, will explore potential synergies that may eventually present new and effective treatment options for difficult to treat cancers of the head and neck. We will be following the progress of the study very carefully. You may remember that a previous multi-institutional study provided evidence that the use of Cesium-131 was surgical resection is well tolerated in the treatment of recurrent head and neck cancers. What the study and our efforts to expand the use of Cesium-131 for the treatment of hard to treat cancers demonstrates is that we remain committed to continuing to be a force of leadership in the field of brachytherapy and making a difference for patients and the doctors who treat them. In fiscal year 2020, IsoRay's continue to see an increase in the treatment of patients with brain cancer. Through orders of Cesium-131 to power GammaTile and for other non-GammaTile cancer applications, we continue to believe the brain cancer remains an area of considerable potential growth. Since our partners at GT Medical Technologies launched into full market release from the beginning of 2020, the Company now has GammaTile available in 26 hospitals across the United States. In addition, GT Medical Technologies recently announced that the University of Texas, MD Anderson Cancer Center will begin enrollment of a multi-center, randomized Phase III clinical trial of GammaTile therapy. This study will compare outcomes of 180 patients with newly diagnosed, large brain tumors